Actionable news
All posts from Actionable news
Actionable news in BLUE: bluebird bio, Inc.,

Goldman Is Buying: Bluebird Bio Off To 'Flying Start'

Trade with confidence. Are you a professional trader? Be the first to get the alert with Benzinga Pro's real-time newsfeed and audio squawk and never miss an opportunity again.
Don't miss the chance to try it FREE today.

bluebird bio Inc BLUE 0.61% is scheduled to present interim data from the Phase II/III study of its lead gene therapy Lenti-D in the pediatric neurodegenerative disease, CCALD, at the plenary session of the American Academy of Neurology (AAN), on April 20.

Goldman Sachs’ Salveen Richter...